Alkermes Announce Completion Of Merger Between Alkermes And Elan Drug Tech

Alkermes and Elan Corporation announced the completion of the merger between Alkermes and Elan Drug Technologies , the drug formulation and manufacturing business unit of Elan. The businesses were combined under a newly-formed company, Alkermes, which is incorporated in Ireland and headquartered in Dublin.

Under the terms of the business combination agreement, Elan Corporation receives $500 million in cash and 31.9 million ordinary shares of Alkermes, representing approximately 25% of Alkermes. Based on the closing share price of Alkermes on September 15, 2011 of $16.52, this represents a total transaction value of approximately $1.0 billion.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.